Monika Håkerud and co-workers publish paper demonstrating that the PCI technology can significantly enhance in vivo vaccination
Monika Håkerud from Kristian Berg’s group at the Department of Radiation Biolgy is first author on an important pre-clinical work on the use of the photochemical internalization (PCI) technology to improve vaccination for stimulation of cytotoxic T cells. The article - entitled "Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen" - was recently published in the Journal of Controlled Release (journal IF 7.6). Håkerud is currently a visiting scientist in Pål Johansen’s lab at the University Hospital Zurich, Switzerland.
The study demonstrates that PCI can facilitate targeting of protein antigen to cytosol and thereby enable MHC class-I antigen presentation and stimulation of CD8 T cells as measured by proliferation and pro-inflammatory cytokine secretion. Most importantly, PCI-based vaccination hampered growth of CD8 T-cell-sensitive malignant tumours in mice. This fruitful academic-industry collaboration was initiated when Pål K. Selbo (co-author in paper and member of Kristian Berg group) introduced the PCI technology for the Zurich group in 2010.
Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen.
Håkerud M, Waeckerle-Men Y, Selbo PK, Kündig TM, Høgset A, Johansen P.
J Control Release. 2013 Nov 23.